Clene Nanomedicine, Inc.

Tottenham Acquisition I Limited (Nasdaq: TOTA) was a blank-check company that completed its initial public offering in 2020 and announced a definitive business combination agreement with Clene Nanomedicine, Inc. in September 2020. Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on central nervous system diseases, developing nanotechnology-based therapeutics targeting conditions including ALS and multiple sclerosis. The transaction is categorized under the diversified sector and closed in late 2020, with the combined company subsequently trading on Nasdaq under the ticker CLNN. The deal is currently recorded as closed across SPAC tracking platforms. Sign up at SpacDesk for the full filing history, timeline, and analytics on this transaction and thousands of other SPACs.

SPAC Counterparty (1)